Advances in multimodal data integration for drug efficacy prediction: Methodological evolution and clinical translation

Fang JW, Wang ZH, Shao JH, Fan JW, Luo QC

Drug Discov Ther. 2026; 20(4):280-292.

DOI: 10.5582/ddt.2026.01042

Duzhong Fang (DZF) alleviates rotenone-induced Parkinson's disease-like pathological alterations through regulation of the gut-brain axis via the intestinal TPH1/5-HT pathway

Li LL, Lv AR, Yang JB, Li XR, Yan ZS, Zhong ZY, Tian WQ, Jia B, Zhang YJ, Zhuang PW, Guo H

Drug Discov Ther. 2026; 20(4):293-308.

DOI: 10.5582/ddt.2026.01045

Unveiling the allosteric inhibition mechanism of SARS-CoV-2 main protease and discovery of a novel allosteric inhibitor

Zhang Q, Wen T, Li M, Tang X

Drug Discov Ther. 2026; 20(4):309-321.

DOI: 10.5582/ddt.2026.01050

Simultaneous determination of belzutifan and cabozantinib, oral agents for renal cell carcinoma, in human plasma using high-performance liquid chromatography

Gando Y, Yasu T

Drug Discov Ther. 2026; 20(4):322-328.

DOI: 10.5582/ddt.2026.01033

Nicotine administration selectively inhibits kainate-induced Arc and junB but not c-fos and egr1 mRNA expression in mouse cerebral cortex

Ihara D, Kato Y, Tabuchi A

Drug Discov Ther. 2026; 20(4):329-334.

DOI: 10.5582/ddt.2026.01034

Sensory testing assessment of dosage forms designed to resist overdose

Nagashima K, Tanaka R, Owase F, Sekine Y

Drug Discov Ther. 2026; 20(4):335-342.

DOI: 10.5582/ddt.2026.01036

Disproportionality analysis of opioid-related urinary retention using the JADER database: Focus on the lack of signal for transdermal fentanyl

Tanaka Y, Kimura M, Ide N, Sako KI, Maeda T

Drug Discov Ther. 2026; 20(4):343-348.

DOI: 10.5582/ddt.2026.01040

Acitretin-inspired medicinal chemistry for Alzheimer's disease: A biomarker-gated central nervous system (CNS) discovery framework

Qin TQ, Han Y

Drug Discov Ther. 2026; 20(4):349-353.

DOI: 10.5582/ddt.2026.01054

Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia

Sun YY, Gao JJ

Drug Discov Ther. 2026; 20(4):354-356.

DOI: 10.5582/ddt.2026.01051

Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1)

Sun YY, Gao JJ

Drug Discov Ther. 2026; 20(4):357-359.

DOI: 10.5582/ddt.2026.01056